Clinical Trial Update: A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease [Phase 2]

View source ↗

Summary

A single-site, randomized, double-blind, placebo-controlled Phase 2 trial of NIC5-15 in Alzheimer's disease completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• NIC5-15

Snippet

Sponsor: Humanetics Corporation | Conditions: Alzheimer's Disease, Dementia | Phase 2 | Status: COMPLETED